Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiazinamium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.48 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.48 |
| ▸ | DRD1 | P21728 | 4/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiazinamium SCHEMBL29714760 | 1.00 | PTGS1 (0.50) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL4425937 | 0.86 | PTGS1 (0.65) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL29856760 | 0.85 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11619269 | 0.85 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL635014 | 0.85 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11617990 | 0.85 | PTGS1 (0.63) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Thiazinamium SCHEMBL11613970 | 0.84 | PTGS1 (0.55) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| SCHEMBL3329470 | 0.78 | PTGS1 (0.61) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| SCHEMBL13257618 | 0.75 | PTGS1 (0.61) | PTGS1PTGS2CYP2D6CHRM2HTR1A | |
| Ammonia Solution, Strong SCHEMBL11612875 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2CYP2D6CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038517-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2020-02-06 | — | — | US | claimed |
| US-20180243429-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2018-08-30 | — | — | US | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| EP-2007394-B1 | NOVEL USE OF ANTIHISTAMINE AGENTS FOR THE PREVENTIVE OR EARLY TREATMENT OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGERED BY TOGAVIRUSES | PF MEDICAMENT (FR) | 2012-10-10 | — | — | EP | claimed |
| US-8242110-B2 | Prevention of alphavirus caused arthritis with antihistamines such as alimemazine; antiserotonin agent and antihistamine combination therapy | PIERRE FABRE MEDICAMENT (FR) | 2012-08-14 | — | — | US | claimed |
| US-20120046279-A1 | Oligomer-Phenothiazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-02-23 | — | — | US | claimed |
| CN-102300588-A | Oligomer-phenothiazine conjugates | — | 2011-12-28 | — | — | CN | claimed |
| EP-2391386-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | Nektar Therapeutics (US) | 2011-12-07 | — | — | EP | claimed |
| WO-2010088340-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-08-05 | — | — | WO | claimed |
| US-20090069308-A1 | Novel Use of Antihistamine Agents for the Preventive or Early Treatment of Inflammatory Syndromes, in Particular Those Triggered by Togaviruses | PIERRE FABRE MEDICAMENT (FR) | 2009-03-12 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| CN-122053287-A | Cluster communication method, electronic device, storage medium, and program product | 中移(苏州)软件技术有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12403094-B2 | Rheological solid oral composition | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12372536-B2 | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-4377558-A | POLYMERIZATION OF P-TRICHLORO-N-DICHLOROPHOSPHORYL-MONOPHOSPHAZENE | INSTITUT MONDIAL DU PHOSPHATE (MA) | 1983-03-22 | — | — | US | disclosed |
| EP-0026685-A1 | Linear polychlorophosphazenes, process for their preparation and their use | Association dite: INSTITUT MONDIAL DU PHOSPHATE (MA) | 1981-04-08 | — | — | EP | disclosed |
| US-4097596-A | BRONCHODILATOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243429-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | HTT, MAPT, SLCO1B3 | CHRM1 901/4885CHRM3 522/4885ACHE 886/4885 |
| US-20200038517-A1 | OLIGOMER-PHENOTHIAZINE CONJUGATES | HTT, MAPT, SLCO1B3 | CHRM1 901/4885CHRM3 522/4885ACHE 886/4885 |
| US-20120046279-A1 | Oligomer-Phenothiazine Conjugates | HTT, MAPT, SLCO1B3 | CHRM1 901/4885CHRM3 522/4885ACHE 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.